Table 5.
Targeted agents in development for the treatment of patients with advanced ovarian cancer
| Agent | Target/MOA | Structure | Company | Phase |
|---|---|---|---|---|
| Folate receptor α (FRα) targeting | ||||
| Mirvetuximab soravtansine (IMGN853) (M9346A antibody + maytansinoid DM4) |
FRα/microtubule inhibitor | ADC | ImmunoGen | I–III |
| MORAb-202 (farletuzumab + eribulin) |
FRα/microtubule inhibitor | ADC | Eisai | I–II |
| Tissue factor targeting | ||||
| Tisotumab vedotin (HuMax-TF-ADC) (antibody + MMAE) |
Tissue factor targeting/microtubule inhibitor | ADC | Genmab/Seattle Genetics | II |
| PTK7 targeting | ||||
| PF-06647020 (antibody + auristatin 0101) |
PTK7 targeting/microtubule inhibitor | ADC | Pfizer/AbbVie | I |
| Protein kinase inhibition | ||||
| Adavosertib (AZD1775) | WEE1 TK inhibitor | SMI | AstraZeneca | II |
| Alpelisib (BYL719) | PI3K-α inhibitor | SMI | Novartis | Ib |
| Ralimetinib (LY2228820 dimesylate) | p38 MAPK1 inhibitor | SMI | Lilly | Ib/II |
| Prexasertib (LY2606368) | CHK 1/2 inhibitor | SMI | Lilly | II |
| AZD6738 | ATR PK inhibitor | SMI | AstraZeneca | II |
| Berzosertib (M6620, VX-970/VE-822) | ATR PK inhibitor | SMI | Merck Serono | II |
ADC: antibody-drug conjugate, ATR: ataxia telangiectasia mutated and Rad3-related kinase, CHK: cell cycle checkpoint, FGF: fibroblast growth factor, HDAC: histone deacetylase, Hsp: heat shock protein, MAPK: mitogen-activated protein kinase, MMAE: monomethyl auristatin E, MOA: mechanism of action, PDGF: platelet-derived growth factor, PI3K: phosphatidylinositol 3-kinase, PK: protein kinase, SMI: small-molecule inhibitor, TK: tyrosine kinase, VEGF: vascular endothelial growth factor, VEGFR2: VEGF receptor 2.